New hope for tough pancreatic cancer: experimental combo tested

NCT ID NCT07235202

Recruiting now Disease control Sponsor: Shenzhen Majory Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults with this type of cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Locations

Beijing Tsinghua Changgung Hospital
RECRUITING

Beijing, Beijing Municipality, 102218, China
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150081, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
ACTIVE_NOT_RECRUITING

Guangzhou, Guangdong, 510000, China
The First Hospital of Jilin University
NOT_YET_RECRUITING

Changchun, Jilin, 130015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.